Abundant levels of the hyperactive low molecular weight (LMW) forms of cyclin E contribute to deregulation of Cdk2 in breast tumors, but the mechanism through which they arise is not fully understood. Here, we explored the hypothesis that post-translational processing by a protease generates the LMW forms of cyclin E in breast tumors. In ZR75 tumor cell lysates, calcium-induced cyclin E truncation into peptides corresponding in size with LMW forms of cyclin E in tumor tissues. Calpeptin inhibited calcium-stimulated cyclin E truncation, indicating that cleavage resulted from activity of the calciumdependent protease, calpain. Consistently, calcium+cal-pain caused truncation of cyclin E immunoprecipitated from tumor cells and tissues. Calcium also caused truncation of the calpain regulatory subunit in tumor cell lysates, indicating that elevated calpain activity accompanies cyclin E truncation. Increased levels of the calpain small subunit were also observed in breast tumors, and significant amounts of its proteolyzed forms indicated increased calpain activity. While elastase also caused cyclin E truncation, the cleavage pattern was distinct from that generated by calpain, suggesting discrete mechanisms in regulating the formation of LMW cyclin E in breast tumors. Treatment of ZR75 cultures with calcium+A23187 recapitulated the formation of the calcium/calpain-induced LMW forms of cyclin E. Altered calcium homeostasis and/or inability of the endogenous calpain inhibitor to control the activity of high levels of the calpain small subunit may contribute to increased calpain activity in breast tumors, causing abundant levels of LMW cyclin E.
Abundant levels of the hyperactive low molecular weight (LMW) forms of cyclin E contribute to deregulation of Cdk2 in breast tumors, but the mechanism through which they arise is not fully understood. Here, we explored the hypothesis that post-translational processing by a protease generates the LMW forms of cyclin E in breast tumors. In ZR75 tumor cell lysates, calcium-induced cyclin E truncation into peptides corresponding in size with LMW forms of cyclin E in tumor tissues. Calpeptin inhibited calcium-stimulated cyclin E truncation, indicating that cleavage resulted from activity of the calciumdependent protease, calpain. Consistently, calcium+cal-pain caused truncation of cyclin E immunoprecipitated from tumor cells and tissues. Calcium also caused truncation of the calpain regulatory subunit in tumor cell lysates, indicating that elevated calpain activity accompanies cyclin E truncation. Increased levels of the calpain small subunit were also observed in breast tumors, and significant amounts of its proteolyzed forms indicated increased calpain activity. While elastase also caused cyclin E truncation, the cleavage pattern was distinct from that generated by calpain, suggesting discrete mechanisms in regulating the formation of LMW cyclin E in breast tumors. Treatment of ZR75 cultures with calcium+A23187 recapitulated the formation of the calcium/calpain-induced LMW forms of cyclin E. Altered calcium homeostasis and/or inability of the endogenous calpain inhibitor to control the activity of high levels of the calpain small subunit may contribute to increased calpain activity in breast tumors, causing abundant levels of LMW cyclin E. Oncogene (2003 Oncogene ( ) 22, 769-774. doi:10.1038 Keywords: cyclin E; calpain; breast cancer Numerous genetic abnormalities have been associated with breast cancer including activation or overexpression of oncogenes, and inactivation of tumor suppressor genes. In addition, aberrant expression and activity of cell cycle related genes have been observed in a variety of breast cancers (Ford et al., 1998; Steeg and Zhou, 1998; Lelekakis et al., 1999) . Cyclin E, a regulatory subunit of Cdk2 that plays an important role in G 1 /S transition, is overexpressed and exists as low molecular weight (LMW) forms in breast cancer cells and tissues (Buckley et al., 1993; Keyomarsi and Pardee, 1993; Keyomarsi et al., 1995; Keyomarsi and Herliczek, 1997; Harwell et al., 2000) . In breast cancer, cyclin E is the most consistent marker for determining the prognosis of early-stage carcinoma (Dou et al., 1996; Harwell et al., 2000) . In fact, expression of LMW cyclin E, which could give rise to constitutively active Cdk2/cyclin E complexes (Keyomarsi et al., 1995) , was shown to strongly correlate with the stage, severity, and outcome of breast cancer (Nielsen et al., 1996; Ford et al., 1998) . However, despite the obvious significance of the LMW forms of cyclin E in breast cancer, few studies have been dedicated to investigate how these smaller cyclin E proteins are generated.
It has been reported that LMW cyclin E are not products of genomic rearrangement of the gene (Keyomarsi et al., 1995) . While several alternative splice variants of cyclin E have been identified (Sewing et al., 1994; Keyomarsi et al., 1995; Ohtsubo et al., 1995; Keyomarsi and Herliczek, 1997) , they are expressed at about the same levels in normal and tumor cells. Thus, these splice variants are distinct from the cyclin E LMW forms that are highly expressed in tumor cells. A few mechanisms for the generation of LMW cyclin E have been suggested, including alternative translation start or stop sites, but the cyclin E gene does not have enough start codons to account for the range of LMW forms (Keyomarsi and Herliczek, 1997) . Recently, it was suggested that LMW forms of cyclin E result from post-translational processing by a protease that is more active in tumor cells (Harwell et al., 2000) . In this study, we sought to identify this potential protease that may be highly active in breast tumors, causing the formation of the LMW forms of cyclin E.
Initially, we examined certain breast tumor cells and tissues for the expression of cyclin E, including its LMW forms. Lysates of four different breast tumor cell lines and homogenates of six different breast tumor tissues were analysed parallel to normal human mammary epithelial cells (HMEC) and a normal tissue adjacent to a breast tumor. As shown in Figure 1a , the total amount of cyclin E was generally greater in tumor cells (lanes 9-12) and tissues (lanes 2-7) compared to that of normal cells (lane 8) and tissue (lane 1). Except for the ZR-75 tumor cell line, the tumor cells and tissues examined showed considerable truncation of cyclin E, with apparent molecular weights ranging from 32 to 48 kDa. These correspond in size with the LMW forms of cyclin E reported previously (Keyomarsi and Pardee, 1993; Said and Medina, 1995) .
To investigate the mechanism behind the formation of LMW cyclin E, we used the breast tumor cell line, ZR75, which shows relatively fewer cyclin E LMW forms compared to the other tumor cell lines that we have examined. Therefore, upon stimulation, any further truncation of cyclin E in ZR75 cells can be readily observed. We then treated ZR75 cell lysates with salts that could potentially induce cyclin E truncation. As shown in Figure 1b Although cyclin E is an ubiquitin-proteasome substrate, and proteolysis through this pathway may be regulated by Ca
2+
, it was suggested that the proteolytic processing of cyclin E in tumor cells is discrete from the proteolytic destruction that occurs via the ubiquitinproteasome pathway (Porter et al., 2001) . Indeed, the LMW forms of cyclin E in tumor tissues are more likely formed by a processing protease, as these truncated peptides are more active than the intact protein (Porter et al., 2001) . We therefore, proceeded to investigate the possibility that LMW cyclin E in breast tumors are generated via post-translational proteolysis by the Ca 2+ -activated protease, calpain. As shown in Figure 1c , when the ZR75 tumor cell lysate was incubated with Ca 2+ in the absence of exogenous protease inhibitors (lane 3), cyclin E was completely truncated, with the 35 kDa form as the major band, and the 42 and 34 kDa forms as minor bands. Although cleavage sites that are target sequences for a serine protease have been identified in cyclin E (Hinds et al., 1992) , aprotinin (lane 4), antipain (lane 6), and PMSF (lane 7) did not have an inhibitory effect on the Ca 2+ -dependent cleavage of cyclin E, and leupeptin (lane 5), which has limited specificity for cysteine proteases, only À5 m isoproterenol, were lysed in 50 mm HEPES buffer (pH 7.4, containing 150 mm NaCl, 1 mm EDTA, 1% Triton-100, 1 mm PMSF, and 2 mg/ml each of leupeptin, antipain, and aprotinin) and centrifuged at 15 000 r.p.m. for 10 min. Tissues (0.5-2.0 g) were homogenized in 25 mm HEPES buffer (pH 7.4, containing 250 mm NaCl, 0.1% NP 40, 1 mm PMSF, 2 mg/ml antipain, and 15 mg/ml benzamidine) and centrifuged at 15 000 rpm for 45 min. The supernatants were used for further analysis. Protein concentration was determined using Bradford's (Bradford, 1976) method. (a) Expression of the LMW forms of cyclin E in breast tumor cells and tissues. Cell lysates or tissue homogenates (50 mg) were analysed by Western blotting using the HE-12 cyclin E antibody (Santa Cruz Biotech., Santa Cruz, CA, USA). Lane 1, normal tissue adjacent to a breast tumor; lanes 2-7, breast tumor tissues from different patients (lanes 3, 6, 7, ER positive; lanes 2, 4, 5, ER negative; lanes 2, 6, 7, stage 2: tumor 2-5 cm, not involving skin and chest wall, movable if involving lymph nodes; lanes 3-5, stage 3: advanced local tumor, fixed to skin or chest wall, or presence of lymph nodes attached to structures in axilla); lane 8, HMEC; lanes 9-12, breast tumor cell lines; asterisks represent bands corresponding to the LMW forms of cyclin E; lower panel, blot in the upper panel was reblotted with an antibody against actin (Santa Cruz Biotech., Santa Cruz, CA, USA Figure 2a . Thus, it seems that Ca 2+ has a parallel effect on cyclin E and the calpain small subunit. This observation is consistent with previous studies indicating that the rate of proteolysis of calpain substrates closely correlates with the rate of autoproteolysis of the calpain regulatory small subunit (reviewed by Croall and Demartino, 1991) . Together, these indicate that the degree of proteolysis of the calpain small subunit reflects the extent of calpain activation.
To further validate our finding that calpain causes cyclin E truncation in breast tumors, we performed a cyclin E cleavage assay in the presence or absence of Ca 2+ or calpain. As shown in Figure 3a , cyclin E immunoprecipitated from ZR75 cell lysates was not affected by either Ca +calpain on cyclin E from tumor tissues resulted perhaps from the more complex nature of tissues. Nonetheless, these results further indicate that cyclin E is a calpain substrate.
Since elastase has previously been shown to selectively cleave cyclin E in vitro (Porter et al., 2001) , we compared the elastase-and calpain-generated LMW forms of cyclin E in breast tumors. Figure 3c shows that while calpain mostly generated the 42 kDa, and 45 and 35 kDa forms of cyclin E (lane 3), elastase mostly generated the 48 kDa form of cyclin E (lane 4), all of which comigrate with LMW forms of cyclin E in a tumor tissue (lane 1). This result may suggest the existence of discrete mechanisms regulating the formation of LMW cyclin E in breast tumors. It is possible that both elastase and calpain contribute to the generation of hyperactive LMW cyclin E in breast tumors.
Given that Ca 2+ +calpain causes cyclin E (immunoprecipitate) truncation that closely resembled those from a tumor tissue further supports a role for calpain in cyclin E cleavage in breast tumors. It seems that LMW cyclin E generated through calpain activity have intact C-terminus, similar to those detected previously in breast tumors (Harwell et al., 2000) , as they can also be detected by an antibody (C-19, Santa Cruz Biotech., Santa cruz, CA, USA) that recognizes the C-terminus (c) Immunoblot analysis using a calpain small subunit antibody (Calbiochem); lanes 1 and 2, HMEC untreated and treated with 500 mm Ca 2+ , respectively; lanes 3-7, ZR75 cell lysates, untreated (lane 3) and treated with 100, 200, 350, and 500 mm Ca 2+ (lanes 4-7, respectively). An asterisk represents bands corresponding to the proteolyzed forms of the calpain small subunit of cyclin E (data not shown). Thus, cyclin E cleavage by calpain likely occurs at the N-terminus. Indeed, the N-terminus was previously proposed as the processing site for the formation of LMW cyclin E (Harwell et al., 2000) .
If calpain contributes to the formation of LMW cyclin E in breast tumors, and the extent of calpain activity can be assessed by the amount of truncated calpain small subunit (reviewed by Croall and Demartino, 1991) , it follows that proteolyzed forms of the calpain small subunit are also present in breast tumors. Indeed, significant amounts of truncated calpain small subunit were present in most of the tumor cells and tissues examined (Figure 4a ), suggesting that calpain activity is generally enhanced or constitutive in breast tumors. Comparison of the amounts of truncated calpain small subunit (Figure 4a , upper panel) with the corresponding amounts of LMW cyclin E (Figure 1a , upper panel) further indicates that the extent of proteolysis of the calpain small subunit correlates with the extent of cyclin E truncation in breast tumor cells and tissues. Consistent with our findings, calpain activity has been associated with mammary malignant transformation (Shiba et al., 1996) . In Figure 4a , we also noted a remarkable increase in intact calpain small subunit expression in breast tumors. Although it was suggested that calpain proteolysis may be unnecessary for calpain activation (Kawasaki and Kawashima, 1996) , the overall increase in intact calpain small subunit seems to readily allow the formation of its smaller forms upon Ca 2+ stimulation, such that elevated calpain activity is easily achieved and, consequently, the formation of LMW cyclin E as well. Further assessment of calpain activity in breast tumor cells (Figure 4b ) revealed upregulated enzyme activity as evidenced by significantly higher levels of the 145 and 150 kDa calpain-specific spectrin breakdown products (lanes 2-5) compared to those in HMEC (lane 1).
We then sought to determine whether the LMW cyclin E generated upon Ca 2+ treatment of tumor cell lysates or Ca 2+ +calpain treatment of cyclin E immunoprecipitates from tumor cells can be generated upon calpain activation in tumor cell cultures. Indeed, we found that calpain activation in ZR75 tumor cells via Ca 2+ +Ca 2+ ionophore (A23187) treatment triggered significant formation of the 42 kDa and minor formation of the 35 and 45 kDa LMW forms of cyclin E. Generation of these LMW cyclin E was inhibited by calpeptin. These findings suggest that calpain may, indeed, cleave cyclin E into its LMW forms in breast tumors. Activation of calpain in the ZR75 cultures was confirmed by corresponding truncation of the calpain regulatory small subunit upon Ca 2+ +A23187 treatment.
The fact that Ca 2+ induces calpain activation and subsequent cyclin E truncation in breast tumor cells but not in HMEC, supports the hypothesis that tumor cells are more susceptible to changes in intracellular Ca 2+ concentration compared to normal cells. This could be because of reduced levels of the Ca 2+ -binding modulator protein, CaN19 (Lee et al., 1992) , which then causes altered Ca 2+ homeostasis and consequently, aberrant calpain activation in breast tumors. Alternatively, elevated calpain activity in breast tumors could be because of reduced levels of the endogenous calpain inhibitor, calpastatin. It is feasible, however, that altered levels of both CaN19 and calpastatin contribute to upregulated calpain activity, which then causes increased generation of the LMW forms of cyclin E. Generation of hyperactive LMW cyclin E by calpain is consistent with the nature of calpain-catalyzed proteolysis, which results in limited alteration and activation rather than proteolytic destruction (Saido et al., 1994) . 2+ and calpain (from lane 7; filled bars). In (c), the effect of calpain+Ca 2+ on ZR75 cyclin E (immunoprecipitate) truncation was compared with that of elastase (Sigma), which was used as described previously (Porter et al., 2001) . Asterisk represents the 48 kDa LMW form of cyclin E generated in elastase-treated cyclin E immunoprecipitate. Note the formation of a 45 kDa LMW form of cyclin E in the calpain+Ca 2+ -treated cyclin E immunoprecipitate Presumably, high concentrations of intact and LMW cyclin E result in constitutively active Cdk2, causing acceleration of the G 1 phase of the cell cycle. Indeed, the LMW forms of cyclin E have been shown to strongly correlate with the stage, severity, and outcome of breast cancer (Nielsen et al., 1996; Ford et al., 1998) . 
